Conditions: Relapsing Multiple Sclerosis
Keywords: Subcutaneous Extension Interferon MS PEGylated Injectable SC PEG peginterferon beta-1a Relapsing
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1077
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.

Detailed description:

Arms:
arm 1: 125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years. arm 2: 125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.

Interventions: intervention 1: peginterferon beta-1a
Intervention descriptions: intervention 1: Administered as specified in the treatment arm

Protocol document: